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                                                         ABSTRACT 
Human African trypanosomiasis (HAT) , also known as sleeping sickness, is one of Africa's 
'neglected diseases', and is caused by infection with protozoan parasites of the Trypanosoma 
genus. Transmitted by the bite of the tsetse fly, it puts 70 million people at risk throughout 
sub-Saharan Africa, and is usually fatal if untreated or inadequately treated. In this brief 
overview some important recent developments in this disease are outlined. These cover 
various aspects including a reduction in disease incidence,  newly recognised  parasite 
reservoir sites in humans, disease outcome, novel diagnostic methods, new and improved 
treatment, and disease neuropathogenesis. 
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Human African trypanosomiasis ( HAT), which is also called sleeping sickness, continues as 
one of Africa's major killer diseases which is greatly feared and occurs in 36 countries 
throughout sub-Saharan Africa where 70 million people are at risk of the disease (1-3 ). HAT 
is caused by protozoan parasites of the genus Trypanosoma which are transmitted to the 
susceptible host via the bite of the blood-sucking tseste fly of the genus Glossina (1,2 ). The 
two variants of  HAT are the West African form caused by Trypanosoma brucei gambiense 
(T.b.gambiense) and the East African form caused by Trypanosoma brucei rhodesiense 
(T.b.rhodesiense), resulting in a disease lasting months to years in the former case and an 
acute disease lasting a few weeks in the latter case (1,3 ). While T.b.gambiense  causes about 
95-97% of total HAT cases, with T.b.rhodesiense  causing about 3-5% of all cases, the latter 
variant constitutes about 18% of the total disease risk and is also causes about two thirds of 
HAT cases in US and European visitors to the East African safari parks (4,5 ). In the early ( 
stage 1) haemolymphatic phase of  infection after the initial bite of the tsetse fly, the parasites 
multiply and spread throughout the bloodstream, lymphatic system and systemic organs, 
following which the parasites cross the blood-brain barrier (BBB) to enter the central nervous 
system (CNS) causing the late (stage 2) encephalitic phase resulting in a wide variety of 
neurological symptoms (6). If untreated, or inadequately treated, HAT is almost always fatal.  
Over the last few years there have been several advances in this field and in this brief 
updating overview some of these are outlined. Overall, the advances have been in the disease 
incidence, the parasite reservoir sites in humans, disease outcome, novel diagnostic methods, 
new and improved treatment, and disease neuropathogenesis.  
The precise incidence of HAT has always been difficult to determine and an influential 
World Health Organisation (WHO) report in 1998 suggested that there were at that time 
about 300,000 new  cases of HAT every year (7). While it is possible that this may have 
overestimated the true incidence of the disease, which is difficult to determine accurately, the 
rapid and progressive decline in the annual number of new cases of HAT since then has been 
impressive. This result has been achieved as a result of the combined and coordinated work 
of  WHO, African governments, non-governmental organisations, charities and other bodies ( 
1). Thus, in 2009 WHO estimated that there were as few as 9878 new HAT cases per year , 
and by 2014 the number of reported cases was reduced to 3796 cases ( with <15,000 
estimated new cases) (2,8) , and by 2016 the figure was further reduced to 2184 new cases 
per year (9). It is therefore not surprising that WHO perceives as realistic goals both the 
elimination of  sleeping sickness as a public health problem by 2020 and the achievement of   
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interruption of its transmission by 2030 (9). It should be appreciated, however, that HAT 
caused by T.b.rhodesiense  will be extremely difficult to eliminate in the future because cattle 
are the animal reservoirs of the human parasites ( as opposed to the human reservoir of the 
parasites causing T.b.gambiense ) and mass culling of cattle is neither desirable nor probably 
achievable . However, by combining vector control to limit the tsetse fly population with 
isolation and treatment of humans with T.b.gambiense, the latter disease may be potentially 
eliminated. 
An important recent finding in this context is the remarkable observation that in  humans the 
skin is a reservoir for the trypanosome parasites (10 ). This finding of extravascular 
trypanosomes occurred in skin biopsies from individuals who were undiagnosed and in whom 
parasites could not be detected in the blood. In experimentally infected mice the authors also 
found that parasites could be detected in their skin and could even be transmitted to a tsetse 
fly vector (10). These striking findings call into question the long term goal of disease 
elimination and may also have great relevance to current diagnosis and treatment. 
While HAT is usually a fatal disease in the absence of adequate treatment, more recent 
studied have indicated that this is not always the case. A small number of infected individuals 
appear to be tolerant of or resistant to trypanosomal infection without exhibiting any clinical 
features of disease in an analogous way to certain breeds of cattle such as the Ndama and 
West African Shorthorn which have been shown to be trypanotolerant with genetically 
determined resistance to infection (9,11). Thus, a few patients with T.b.gambiense  infection 
maintain an asymptomatic state and can be aparasitaemic and also  seropositive or even 
seronegative (12,13 ). Some of these individuals had either declined treatment or had self-
cured, with the latter being regarded as resistant rather than tolerant of infection (12,13). It is 
currently unknown just how widespread this phenomenon is or whether patients who are 
tolerant and seropositive  pose a risk of infection to others and so should be treated 
accordingly. Relevant to this is the recent report of  a man infected with T.b.gambiense  who 
had survived 29 years with the disease (14). Whether prolonged survival with disease is a 
rarity or more common than had previously been thought remains to be seen. 
Diagnosis of HAT should ideally always be established by direct visualisation of the 
trypanosomes in the blood or lymph nodes when samples are examined under a microscope. 
While this is usually possible in T.b.rhodesiense  cases because of the high levels of 
parasitaemia, this may well not be possible in the case of T.b.gambiense  infection where the 
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parasitaemia is cyclical, possibly related to a greater adaptation of the parasite to the host 
(1,3,11 ). Therefore serological methods have been used for several years in the latter case. 
Recently, so-called Rapid Diagnostic Tests (RDTs) such as the SD BIOLINE HAT have been 
developed which have high specificities and sensitivities, and which use serological 
techniques to recognise a variety of trypanosome antigens such as different Variable Surface 
Glycoproteins (VSG) (15,16 ). These RDTs may supersede the older Card Agglutination Test 
for Trypanosomiasis (CATT) which is useful as a screening test and especially in regions of 
high HAT incidence. However it should be appreciated that a positive RDT may not 
necessarily establish that an infection has occurred as it may just reflect an anti-trypanosomal 
immune response to a bite by an infected fly, and also it is unable to distinguish between an 
active trypanosomal infection and a previous exposure to HAT which may have been treated 
successfully (9). Nevertheless the advent of RDTs represents a very useful addition to the 
diagnostic armamentarium for HAT. 
Diagnostic staging to distinguish between the early and late stage of HAT is also extremely 
important to achieve, especially in view of the toxic nature of drugs for CNS disease ( see 
below), but unfortunately this has proved very problematic in practice. The WHO criteria for 
the definition of late-stage ( CNS) disease is based on the examination of the cerebrospinal 
fluid (CSF) by lumbar puncture  (LP) and is the presence of >5 White blood cells 
(WBC)/mm3 and /or the presence of trypanosomes (1,3 ). While widely used, this criterion is 
not generally accepted with different physicians using different CSF WBC criteria to define 
late stage disease. There is also a dissociation between the biological definition of late stage 
disease and the criteria used for instigating late stage drugs (3). Although several reports have 
purported to show novel CSF criteria for defining CNS disease ( 1,9 ) these have all been 
compared to the WHO CSF criteria which certainly do not represent a gold standard. This 
'circular argument problem' has persisted and has recently been discussed in detail (17 ). 
While drug therapy for early stage HAT has been effective and only mildly toxic intravenous 
[IV] suramin for T.b.rhodesiense  and intramuscular or IV pentamidine for T.b.gambiense ), 
the drugs currently used for late stage disease are very toxic ( 1-3). Melarsoprol is the first 
line drug for CNS T.b.rhodesiense  and, while effective, it is very painful to administer and 
causes a post-treatment reactive encephalopathy (PTRE) in about 10% of cases about half of 
which are fatal and recent studies indicate a fatality rate of about 6% with this drug (1,2). 
Melarsoprol is also effective against CNS T.b.gambiense  but was superseded as first line 
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therapy by NECT ( nifurtimox-eflornithine combination therapy) for this variant ( 18) , but 
this drug combination  is ineffective against  CNS T.b.rhodesiense  (1). An orally effective 
drug  for late -stage disease that is free of side effects would therefore be of great therapeutic 
value and might also obviate the requirement for an LP to analyse the CSF. Over the last few 
years several novel and orally administered drugs for CNS HAT have therefore been 
developed, or are in the process of development, or are under critical evaluation.  
In a randomised  phase 2/3 study over a period of 18 months in the DRC and Central African 
Republic, it was recently reported that the nitroheterocyclic drug  oral fexinidazole was 
successful in treating 91% of  patients with late-stage T.b.gambiense  disease compared with 
a success rate of 98% of patients who had been treated with NECT (19).  The side-effects 
attributed to the two therapies were similar. This is a significant advance though the 
European Medicines Agency (EMA) noted that in the subpopulation of patients with a CSF 
WBC of >100/mm3 the efficacy of fexinidazole was 86.9% compared with 98.7% in the 
NECT arm indicating that the risk of failure was greater with fexinidazole in this subgroup 
(20). For this reason the EMA recommended that  HAT patients with CSF WBC of >100/ 
mm3 should only be treated with fexinidazole if no other adequate treatment such as NECT is 
available or tolerated. Further studies with fexinidazole are awaited including the extent to 
which it may or may not be effective in cases of late-stage HAT due to T.b.rhodesiense.  
There are also other novel oral drugs in the pipeline. A notable one is a compound called 
SCYX-7158 which is a member of the oxaborole group. In a mouse model of HAT this drug 
cured late-stage disease, and was also shown to have a good safety profile in a phase 1 study 
in humans (21 ). It is now undergoing evaluation in a phase 2/3 trial in CNS HAT and the 
results are eagerly awaited. A different approach has been to modify the melarsoprol drug 
itself to make it less toxic but orally administered and equally efficacious. Melarsoprol 
cyclodextrin inclusion complexes ( 'complexed melarsoprol) , which are constructed by 
incorporating the melarsoprol drug into a cyclodextrin molecule, were shown to be effective 
in curing late-stage disease in a very well established mouse model of HAT while also being 
free of over toxic effects (22). This drug now has dual EMA/ US Food and Drug 
Administration (FDA) designation as an 'orphan drug' for the treatment of African sleeping 
sickness. The EMA has also approved a trial protocol for a first in man phase 2 trial of this 
drug in T.b.rhodesiense HAT. It is hoped that such a trial can start in the near future. 
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Recent advances in our understanding of disease neuropathogenesis have been steady but, in 
my view, incremental rather than dramatic. A crucial tool in this respect has been the use of 
experimental animal models of early and late stage HAT, in particular the use of a highly 
reproducible mouse model which closely mirrors the human disease both clinically and 
neuropathologically (11,23). Two particular, and related, areas of advancement have been the 
use of modern imaging techniques such as Magnetic Resonance Imaging (MRI) and 
bioluminescence imaging to better understand the disease, and also a focus on BBB function 
at various stages of disease progression. Thus MRI can be used to assess the degree of BBB 
damage, which can be quantified, during experimental trypanosomiasis infection, and this has 
been shown previously not to correlate with the degree of inflammatory cell infiltration 
(24,25 ). Leaking of contrast agent within the BBB, indicating impairment, has also been 
shown to occur prior to the development of CNS disease , and this BBB damage progresses 
as the disease advances (24). Bioluminescence imaging has also been applied to experimental 
HAT infection. For example, it was recently shown  that using such non-invasive imaging 
with intravital multi-photon microscopy and a genetically modified  Trypanosoma brucei 
brucei expressing luciferase, trypanosomes enter the brain meninges as early as day 5 
postinfection ( 26). Such technology should prove useful during the process of drug screening 
for treating trypanosomiasis infections. The modern notion of an early invasion of 
trypanosomes into the CNS was also supported in such a murine model in a study using  
intravital brain imaging where  bloodstream forms of T. b. brucei and T. b. rhodesiense 
entered the brain parenchyma within hours, before a significant level of microvascular 
inflammation became detectable and in the absence of overt cerebral injury (27). The 
significance of such early invasion of the brain by the trypanosomes is not yet determined but 
it is consistent with the hitherto surprising presence of neurological features being detected 
during the early-stage of  T. b. rhodesiense infection in HAT patients in Uganda and Malawi ( 
28). Further, the increasing use of genetically modified trypanosomes with specific 
alterations is very likely to enhance our knowledge of the evidently complex interaction 
between host immunological defences and harmful parasite-induced factors, in particular at 
the level of the BBB. 
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